- Home
- SKYH vs BDTX Comparison
SKYH vs BDTX Comparison
Compare SKYH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYH | BDTX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKYH | BDTX |
|---|---|---|
| Price | $9.03 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.83 | $10.60 |
| AVG Volume (30 Days) | 123.2K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | $24,125,000.00 | ★ $70,000,000.00 |
| Revenue This Year | $95.79 | N/A |
| Revenue Next Year | $69.76 | N/A |
| P/E Ratio | ★ N/A | $6.85 |
| Revenue Growth | ★ 95.23 | N/A |
| 52 Week Low | $8.22 | $1.20 |
| 52 Week High | $14.20 | $4.94 |
Technical Indicators
Market Signals| Indicator | SKYH | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 34.12 |
| Support Level | $8.49 | $2.52 |
| Resistance Level | $10.07 | $2.69 |
| Average True Range (ATR) | 0.33 | 0.14 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 34.18 | 28.77 |
Price Performance
Historical ComparisonAbout SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.